On the role of autophagy in the progression of differentiated thyroid cancer (literature review)

On the role of autophagy in the progression of differentiated thyroid cancer (literature review)

The aim of the study was to analyze and summarize available literature data on the role of autophagy in thyroid cancer. Material and methods. We analyzed 34 publications available from pubmed and elibrary. Ru databases concerning thyroid cancer and autophagy. Results. The review discussed the role o...

Full description

Bibliographic Details
Main Authors:	K. A. Garipov, Z. A. Afanaseva, Z. I. Abramova
Format:	Article
Language:	Russian
Published:	Russian Academy of Sciences, Tomsk National Research Medical Center 2022-01-01
Series:	Сибирский онкологический журнал
Subjects:	dfferentiated thyroid cancer resistance to anticancer therapy autophagy molecular-targeted therapy tyrosine kinase inhibitors
Online Access:	https://www.siboncoj.ru/jour/article/view/1996

Similar Items

Progress on Targeted Therapy of Radioiodine-refractory Differentiated Thyroid Cancer
by: TENG Lisong, et al.
Published: (2023-05-01)

The new insights into autophagy in thyroid cancer progression
by: Yu-Bo Shi, et al.
Published: (2023-06-01)

Molecular Therapies in Thyroid Cancer
by: Mark Agulnik, et al.
Published: (2010-12-01)

Recent Updates on the Management of Medullary Thyroid Carcinoma
by: Bo Hyun Kim, et al.
Published: (2016-09-01)

Historical aspects and modern concepts in the treatment of patients with differentiated thyroid cancer, refractory to radioactive iodine therapy
by: E. V. Borodavina, et al.
Published: (2022-02-01)

Efficacy of vandetanib in the treatment of medullary thyroid cancer: literature review and case report
by: А. М. Mudunov, et al.
Published: (2019-10-01)

New Paradigm in Treating Cancer: Right on Target
by: Noorwati Sutandyo
Published: (2016-09-01)

Survival analysis of patients with advanced metastatic differentiated thyroid cancer
by: E. V. Borodavina, et al.
Published: (2022-08-01)

Target Therapy in Thyroid Cancer: Current Challenge in Clinical Use of Tyrosine Kinase Inhibitors and Management of Side Effects
by: Ivana Puliafito, et al.
Published: (2022-07-01)

Multikinase and highly selective kinase inhibitors in the neoadjuvant treatment of patients with thyroid cancer
by: Laura Valerio, et al.
Published: (2025-02-01)

New-generation mutitargeted tyrosine kinase inhibitors in the treatment of radioactive iodine-refractory differentiated thyroid cancer
by: A. M. Mudunov
Published: (2015-06-01)

APOPTOSIS ROLE IN FORMING RADIOIODINE RESISTANCE IN DIFFERENTIATED THYROID CANCER
by: K.A. GARIPOV, et al.
Published: (2020-06-01)

Kinase Inhibitors in the Treatment of Thyroid Cancer: Institutional Experience
by: Matea Pešorda, et al.
Published: (2020-01-01)

Neoadjuvant lenvatinib for inoperable thyroid cancer: A case report and literature review
by: Khalid Alshehri, et al.
Published: (2022-02-01)

Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies
by: Xuejin Ou, et al.
Published: (2024-09-01)

STUDY IN SILICO OF THIOUREA-DERIVED COMPOUNDS AS TYROSINE KINASE RECEPTOR INHIBITORS
by: Budi Mulyati, et al.
Published: (2022-12-01)

Comparison of autophagy inducibility in various tyrosine kinase inhibitors and their enhanced cytotoxicity via inhibition of autophagy in cancer cells in combined treatment with azithromycin
by: Hideki Tanaka, et al.
Published: (2020-07-01)

Current understanding of nonsurgical interventions for refractory differentiated thyroid cancer: a systematic review
by: Heidi Jones, et al.
Published: (2021-08-01)

Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives
by: Ying Zhang, et al.
Published: (2024-09-01)

New Quinoxaline Derivatives as Dual Pim-1/2 Kinase Inhibitors: Design, Synthesis and Biological Evaluation
by: Bruno Oyallon, et al.
Published: (2021-02-01)

Current perspectives on the management of patients with advanced RET-driven thyroid cancer in Europe
by: Rossella Elisei, et al.
Published: (2023-05-01)

Autophagy in thyroid cancer: present knowledge and future perspectives
by: Romana Teodora Netea-Maier, et al.
Published: (2015-02-01)

Tyrosine Kinase Inhibitors for Radioactive Iodine Refractory Differentiated Thyroid Cancer
by: Christos Cortas, et al.
Published: (2023-12-01)

Radioactive iodine-refractory differentiated thyroid cancer: an uncommon but challenging situation
by: Angelica Schmidt, et al.
Published: (2017-02-01)

Adjuvant therapy with imatinib for an incompletely resected multilobular tumour of bone in a dog
by: SH Lee, et al.
Published: (2022-11-01)

Effective palliative treatment of recurrent soft tissue sarcoma in a dog using imatinib mesylate (Gleevec®)
by: G.H. Kim, et al.
Published: (2018-11-01)

Successful response to imatinib in two dogs with inoperable grade III infiltrating mast cell tumours: a case report
by: J.H. Kim, et al.
Published: (2016-08-01)

The Activity and Safety of Anlotinib for Patients with Extremity Desmoid Fibromatosis: A Retrospective Study in a Single Institution
by: Zheng C, et al.
Published: (2020-09-01)

Epidermal Growth Factor Mutation as a Diagnostic and Therapeutic Target in Metastatic Poorly Differentiated Thyroid Carcinoma: A Case Report and Review of the Literature
by: Hazel Lote, et al.
Published: (2014-06-01)

Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective Analysis
by: Soo Young Kim, et al.
Published: (2020-09-01)

LENVATINIB IN TREATMENT OF RADIOACTIVE IODINE-REFRACTORY WELL-DIFFERENTIATED THYROID CARCINOMA
by: I. S. Romanov, et al.
Published: (2017-06-01)

Thyroid dysfunction induced by alectinib in a patient with a non-small cell lung cancer
by: L. Plaza-Enriquez, et al.
Published: (2022-06-01)

Planned drug holidays during treatment with lenvatinib for radioiodine-refractory differentiated thyroid cancer: a retrospective study
by: Chihiro Matsuyama, et al.
Published: (2023-10-01)

Combination of Lenvatinib and Pembrolizumab as Salvage Treatment for Paucicellular Variant of Anaplastic Thyroid Cancer: A Case Report
by: Cristina Luongo, et al.
Published: (2021-12-01)

Protein kinase inhibitors as targeted therapy for glioblastoma: a meta-analysis of randomized controlled clinical trials
by: José Pinto-Fraga, et al.
Published: (2025-02-01)

Tyrosine kinase receptor inhibitor as a molecularly targeted therapy for solid tumors
by: P Sunpaweravong
Published: (2006-01-01)

Disseminated medullary thyroid carcinoma. Optimal approach to treatment
by: I. S. Romanov, et al.
Published: (2019-01-01)

Autophagy Inhibition Enhances Anti-Glioblastoma Effects of Pyrazolo[3,4-<i>d</i>]pyrimidine Tyrosine Kinase Inhibitors
by: Sofija Jovanović Stojanov, et al.
Published: (2022-09-01)

How I Manage Chronic Lymphocytic Leukemia
by: Patrice Nasnas, et al.
Published: (2023-08-01)

BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective
by: Ningning Yan, et al.
Published: (2022-03-01)